These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32421502)

  • 1. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
    Long B; Brém E; Koyfman A
    West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine release syndrome: grading, modeling, and new therapy.
    Liu D; Zhao J
    J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
    Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
    Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
    Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
    Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
    Lipe DN; Shafer S
    Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy with CAR-T cells - behold the future.
    Graham C; Hewitson R; Pagliuca A; Benjamin R
    Clin Med (Lond); 2018 Aug; 18(4):324-328. PubMed ID: 30072559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicity of immune therapies for cancer.
    Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
    BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.
    Lee YG; Chu H; Lu Y; Leamon CP; Srinivasarao M; Putt KS; Low PS
    Nat Commun; 2019 Jun; 10(1):2681. PubMed ID: 31213606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Immunotherapies in Oncology Treatment and Their Side Effect Profiles.
    Sriratana P; Norton J
    J Am Board Fam Med; 2018; 31(4):620-627. PubMed ID: 29986988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
    Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
    Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
    Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
    J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological Immunotoxicity from Cancer Treatment.
    Wesley SF; Haggiagi A; Thakur KT; De Jager PL
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
    Davda J; Declerck P; Hu-Lieskovan S; Hickling TP; Jacobs IA; Chou J; Salek-Ardakani S; Kraynov E
    J Immunother Cancer; 2019 Apr; 7(1):105. PubMed ID: 30992085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.